Every enterprise CMS evaluation eventually surfaces the same question from someone in the room: what if we just build it ourselves? Custom-coded, no platform licensing, no third-party dependency, full control. In most industries, this is a reasonable position to consider. In pharmaceutical digital, it deserves a particularly careful answer — because the consequences of getting it wrong are not just technical. They are regulatory, operational, and in some cases clinical.
What "No CMS" Actually Means
"No CMS" covers a wide range of approaches:
- Fully custom-coded static sites — HTML, CSS, and JavaScript written and deployed directly, with content embedded in code
- Hardcoded templates with manual content updates — a developer edits files directly to update product information, safety copy, or regulatory footers
- Document management systems repurposed as web backends — SharePoint, Confluence, or similar tools used to store and serve web content without a dedicated CMS layer
- Headless databases or spreadsheets driving content — content stored in Airtable, Google Sheets, or a custom database, with a frontend that fetches and renders it
Each has different characteristics, but all share a common property: there is no purpose-built editorial interface, no structured content model, and no built-in workflow or governance layer.
The Real Advantages
Maximum Performance
A custom-coded static site with no CMS overhead delivers the fastest possible page load times. There are no database queries, no template rendering engines, no plugin layers. For high-traffic pharmaceutical pages — a vaccine product page during a public health event, a patient support enrollment form — raw performance is a legitimate concern.
No Vendor Dependency
Enterprise CMS platforms come with vendor relationships, licensing contracts, and upgrade cycles. Building without a platform means your team controls the full technology stack. There are no forced migrations when a vendor changes pricing, no risk of a platform reaching end-of-life.
Exact Data Model
A custom solution can model pharmaceutical content exactly as your regulatory and medical teams need it — without adapting your requirements to the constraints of a platform's content type system. If your safety data structure does not map cleanly to any CMS's field model, custom development gives you complete flexibility.
Lower Initial Licensing Cost
No platform licensing means the initial budget goes entirely to implementation. For small pharmaceutical sites with simple, stable content, the math can favor a custom build over a commercial CMS.
The Real Disadvantages
Every Editorial Change Requires a Developer
In a CMS, a medical writer can update a product page safety statement directly in an editorial interface. Without a CMS, that same change requires a developer to edit code, go through a code review, and deploy. In pharmaceutical environments where safety updates are time-sensitive — a label change, a new contraindication — this creates a dangerous bottleneck.
MLR Workflow Does Not Exist By Default
Medical, Legal, and Regulatory review processes need to be enforced by the system, not by people following an honor system. A CMS enforces workflow at the platform level: content cannot move to the next stage without the appropriate approval. A custom build has no such enforcement. You can build it — but you are now maintaining a custom workflow application on top of your custom website.
Audit Trails Must Be Built and Maintained
Regulators expect documented evidence of who approved content, when, and in what state. Every commercial CMS maintains this automatically. In a custom system, audit trail infrastructure must be designed, built, tested, and maintained. This is not a minor addition — it is a significant engineering project, and any gaps create compliance exposure.
Localization at Scale Becomes Unmanageable
Managing translated content across 10 or 20 markets in a custom system — where each market's safety copy might be different, where updates must propagate correctly, where translation status must be tracked — requires either massive manual coordination or significant custom tooling. CMS platforms solve this problem. Custom builds create it.
Security Responsibility Falls Entirely on Your Team
Commercial CMS platforms have dedicated security teams, coordinated vulnerability disclosure processes, and regular security patches. A custom-built system is only as secure as the team that builds and maintains it. For pharmaceutical sites handling personal health information in HCP portals or patient support programs, this is a serious obligation.
No Editorial Interface for Non-Technical Teams
Medical writers, regulatory affairs professionals, and marketing teams need to manage content without developer involvement. This is one of the core problems that CMS platforms exist to solve. A custom build that lacks an editorial interface effectively locks content behind the engineering team's availability.
When It Actually Makes Sense
Despite the significant disadvantages, there are specific pharmaceutical use cases where a no-CMS approach is genuinely appropriate:
Truly static promotional microsites — a congress campaign landing page with fixed content, a short-term disease awareness microsite with no editorial updates planned. If the content is set at launch and will not change, a custom static build avoids unnecessary platform overhead.
Developer-facing API documentation — pharmaceutical companies increasingly expose APIs for partner integrations, clinical data feeds, and digital health programs. Developer documentation sites have different requirements from patient-facing properties and can legitimately be built with static site generators without a CMS.
Internal tools with a single technical maintainer — a dashboard for regulatory submission tracking, an internal reference tool for field force — small, controlled audiences where the "editor" is the developer.
Proof-of-concept and prototype work — when validating a new digital program before committing to a full platform investment, a custom prototype can test the concept without the overhead of CMS configuration.
The Honest Calculation
For any pharmaceutical digital property that will be updated by non-developers, that must demonstrate compliance, that carries regulatory content, or that serves multiple markets — a no-CMS approach will cost more in the long run than the platform licensing it appears to avoid. The development time to build workflow, audit, localization, and editorial tooling from scratch will exceed the cost of a CMS. And the ongoing maintenance cost will continue indefinitely.
The right question is not "CMS or no CMS" — it is "which CMS matches our actual requirements at an appropriate cost." The platforms that serve pharmaceutical organizations best range from open-source options like Drupal with zero licensing cost, through purpose-built enterprise solutions like Magnolia, to full-scale platforms like Adobe Experience Manager and Sitecore.
If you are evaluating whether to build custom or adopt a platform for a pharmaceutical digital property, explore our CMS Development service or contact our team to discuss your specific requirements.